CMA Sees Fine Over Nortriptyline Upheld In UK
Lexon’s Appeal Dismissed By Competition Tribunal
The UK’s Competition and Markets Authority has welcomed a ruling upholding its finding that Lexon broke competition law in relation to nortriptyline, along with a connected £1.2m fine.
You may also be interested in...
Four firms – Accord, Alissa, Lexon and King – have been fined by the UK’s Competition and Markets Authority over price-fixing and information-sharing activities related to the supply of nortriptyline.
Alissa Healthcare and King Pharmaceuticals have admitted colluding over UK supplies of nortriptyline to keep prices up, following an investigation launched by the country’s CMA.
King Pharmaceuticals and Auden Mckenzie have been accused by the UK’s competition regulator of sharing out the supply of nortriptyline 10mg and 25mg tablets, in a case that also implicates Alissa and Lexon for exchanging commercially-sensitive information as part of an effort to drive up prices.